EMSAM (deprenyl patch): how a promising antidepressant was underutilized.

Area of Science:

• Psychiatry
• Pharmacology
• Neuroscience

Background:

• The EMSAM patch is the only transdermal monoamine oxidase inhibitor (MAOI) antidepressant.
• Clinicians anticipated better tolerability and efficacy compared to oral antidepressants.
• Despite potential, EMSAM remains underutilized in clinical practice.

Purpose of the Study:

• To explore reasons for the underutilization of the EMSAM patch.
• To highlight the potential advantages of EMSAM that are often overlooked.
• To encourage greater clinical interest and use of this unique antidepressant.

Main Methods:

• Review of clinical use, side effect profiles, and existing literature on EMSAM.
• Analysis of factors contributing to underutilization, including safety concerns and research gaps.
• Identification and emphasis on the under-promoted benefits of transdermal MAOI therapy.

Main Results:

• Underutilization is attributed to exaggerated fears of side effects (cheese reaction, serotonin syndrome) and lack of comprehensive studies.
• Key advantages include avoidance of swallowing issues, minimal side effects, low risk of suicidal behavior, and efficacy in anxious and atypical depression.
• The 6 mg/day dose does not necessitate dietary restrictions.

Conclusions:

• Addressing exaggerated safety concerns and conducting further research can improve EMSAM's clinical adoption.
• Highlighting EMSAM's unique benefits, such as its transdermal delivery and favorable side effect profile, is crucial.
• Increased clinical awareness and research may unlock the full potential of EMSAM for treating diverse depressive conditions.